KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Retained Earnings (2017 - 2025)

Historic Retained Earnings for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to $7.1 billion.

  • Takeda Pharmaceutical's Retained Earnings fell 1617.18% to $7.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $7.1 billion, marking a year-over-year decrease of 1617.18%. This contributed to the annual value of $7.8 billion for FY2025, which is 1918.2% down from last year.
  • According to the latest figures from Q4 2025, Takeda Pharmaceutical's Retained Earnings is $7.1 billion, which was down 1617.18% from $7.8 billion recorded in Q3 2025.
  • Takeda Pharmaceutical's Retained Earnings' 5-year high stood at $14.3 billion during Q2 2021, with a 5-year trough of $7.1 billion in Q4 2025.
  • In the last 5 years, Takeda Pharmaceutical's Retained Earnings had a median value of $10.7 billion in 2022 and averaged $10.6 billion.
  • Its Retained Earnings has fluctuated over the past 5 years, first soared by 1571.29% in 2021, then tumbled by 2136.99% in 2022.
  • Over the past 5 years, Takeda Pharmaceutical's Retained Earnings (Quarter) stood at $12.9 billion in 2021, then decreased by 17.3% to $10.7 billion in 2022, then fell by 11.45% to $9.4 billion in 2023, then fell by 10.14% to $8.5 billion in 2024, then decreased by 16.17% to $7.1 billion in 2025.
  • Its last three reported values are $7.1 billion in Q4 2025, $7.8 billion for Q3 2025, and $8.0 billion during Q2 2025.